Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Impel Neuropharma (IMPL) PT Raised to $50 at Guggenheim
September 7, 2021 12:25 PM EDTGuggenheim analyst Eddie Hickman raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $50.00 (from $32.00) while maintaining a Buy rating.
... MoreImpel Neuropharma (IMPL) PT Raised to $31 at Wedbush
September 3, 2021 11:19 AM EDTWedbush analyst Laura Chico raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $31.00 (from $25.00) while maintaining a Outperform rating.
... MoreImpel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval
September 3, 2021 10:57 AM EDTCowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.
The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More
Pre-Open Stock Movers 09/03: (APOP) (IMPL) (MDB) Higher; (FBRX) (YEXT) (JOAN) Lower (more...)
September 3, 2021 9:22 AM EDTPre-Open Stock Movers
Forte Biosciences, Inc. (NASDAQ: FBRX) 80.4% LOWER; announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).
Cellect Biotechnology Ltd. (NASDAQ: APOP) 64% HIGHER; announced the first ApoGraftTM transplantation in a Leukemia patient in the... More
Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval
September 3, 2021 9:18 AM EDTImpel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval
... MoreImpel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for Migraine
September 3, 2021 8:52 AM EDTImpel NeuroPharma, Inc. (NASDAQ: IMPL) announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104.
Using Impels proprietary Precision Olfactory Delivery (POD®) technology, TRUDHESA gently delivers dihydroergotamine mesylate (DHE)a proven, well-established therapeuticquickly to the bloodstream through the vascular-rich upper nasal space.1 TRUDHESA bypasses the gut and potential absorption issues, offering rapid, sustained, and consistent symptom relief without injection or infusion,... More
Impel NeuroPharma Inc. (IMPL) halted, news pending
September 3, 2021 8:25 AM EDTImpel NeuroPharma Inc. (NASDAQ: IMPL) halted, news pending
... More